ERBB2 and breast cancer: The phase II LANDSCAPE trial has investigated the association of capecitabine plus lapatinib as an up-front treatment in HER2-positive BM, reporting an intracranial response rate of 65.9% (95%CI 50.1–75.9%), and suggesting that such a combined therapy, instead of RT, could be a feasible first-line treatment in HER2-positive BM from BC [72].